Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate; crospovidone; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake; indigo carmine aluminium lake; iron oxide red - crosuva is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: crosuva is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). crosuva is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: crosuva is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crosuva, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rosuvastatin calcium, quantity: 5.2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; lactose monohydrate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; triacetin; quinoline yellow aluminium lake; indigo carmine aluminium lake; iron oxide yellow - crosuva is indicated as an adjunct to diet when the response to diet and exercise is inadequate. prevention of cardiovascular events: crosuva is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). crosuva is indicated to: reduce the risk of nonfatal myocardial infarction; reduce the risk of nonfatal stroke; reduce the risk of coronary artery revascularisation procedures. in patients with hypercholesterolaemia: crosuva is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crosuva, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -